Around 2,515 people are employed by Gilead Sciences. (As of January 31, 2007 ). Gilead Sciences has offices in North America, Europe and Australia.
The company's name and logo refer to the biblical site of Gilead.
Gilead Sciences researches and commercializes therapies, such as HIV, hepatitis B, hepatitis C and influenza.
In June 1987, the then 29 - year-old doctor Michael Riordan founded the company Oligogen, Inc., which was renamed in 1988 in Gilead Sciences.
In January 1997, Donald Rumsfeld was Chairman of the Board, its member, he had been since 1988. He resigned from that post when he was defense secretary under George W. Bush. Its stock share is estimated at a value of five to twenty-five million U.S. dollars. He could be even higher, than in the autumn of 2005 drove the increase in demand for Tamiflu (because of the bird flu H5N1) Gilead shares in the height.
Gilead Sciences has the following products on the market (as of January 2009).
- Atripla ( a combination of tenofovir, emtricitabine and efavirenz )
- Emtriva (emtricitabine )
- Hepsera ( adefovir dipivoxil )
- Truvada (emtricitabine and tenofovir disoproxil fumarate)
- Viread ( tenofovir disoproxil fumarate)
- Flolan ( epoprostenol sodium)
- Letairis ( ambrisentan )
- Tamiflu ( oseltamivir phosphate )
- AmBisome ( amphotericin B liposome for injection )
- Macugen ( pegaptanib sodium for injection )
- Vistide ( cidofovir for injections)
The marketing of Mozenavir will not be pursued because no significant advantages over other protease inhibitors were present.